235 related articles for article (PubMed ID: 34061452)
21. Clinical Utilization of Chimeric Antigen Receptor T Cells in B Cell Acute Lymphoblastic Leukemia: An Expert Opinion from the European Society for Blood and Marrow Transplantation and the American Society for Blood and Marrow Transplantation.
Kansagra AJ; Frey NV; Bar M; Laetsch TW; Carpenter PA; Savani BN; Heslop HE; Bollard CM; Komanduri KV; Gastineau DA; Chabannon C; Perales MA; Hudecek M; Aljurf M; Andritsos L; Barrett JA; Bachanova V; Bonini C; Ghobadi A; Gill SI; Hill J; Kenderian S; Kebriaei P; Nagler A; Maloney D; Liu HD; Shah NN; Kharfan-Dabaja MA; Shpall EJ; Mufti GJ; Johnston L; Jacoby E; Bazarbachi A; DiPersio JF; Pavletic SZ; Porter DL; Grupp SA; Sadelain M; Litzow MR; Mohty M; Hashmi SK
Biol Blood Marrow Transplant; 2019 Mar; 25(3):e76-e85. PubMed ID: 30576834
[TBL] [Abstract][Full Text] [Related]
22. Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia.
Maude SL; Laetsch TW; Buechner J; Rives S; Boyer M; Bittencourt H; Bader P; Verneris MR; Stefanski HE; Myers GD; Qayed M; De Moerloose B; Hiramatsu H; Schlis K; Davis KL; Martin PL; Nemecek ER; Yanik GA; Peters C; Baruchel A; Boissel N; Mechinaud F; Balduzzi A; Krueger J; June CH; Levine BL; Wood P; Taran T; Leung M; Mueller KT; Zhang Y; Sen K; Lebwohl D; Pulsipher MA; Grupp SA
N Engl J Med; 2018 Feb; 378(5):439-448. PubMed ID: 29385370
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and safety of tisagenlecleucel in Japanese pediatric and young adult patients with relapsed/refractory B cell acute lymphoblastic leukemia.
Hiramatsu H; Adachi S; Umeda K; Kato I; Eldjerou L; Agostinho AC; Natsume K; Tokushige K; Watanabe Y; Grupp SA
Int J Hematol; 2020 Feb; 111(2):303-310. PubMed ID: 31709501
[TBL] [Abstract][Full Text] [Related]
24. Optimizing Chimeric Antigen Receptor T-Cell Therapy for Adults With Acute Lymphoblastic Leukemia.
Frey NV; Shaw PA; Hexner EO; Pequignot E; Gill S; Luger SM; Mangan JK; Loren AW; Perl AE; Maude SL; Grupp SA; Shah NN; Gilmore J; Lacey SF; Melenhorst JJ; Levine BL; June CH; Porter DL
J Clin Oncol; 2020 Feb; 38(5):415-422. PubMed ID: 31815579
[TBL] [Abstract][Full Text] [Related]
25. Tisagenlecleucel infusion in patients with relapsed/refractory ALL and concurrent serious infection.
Hall EM; Yin DE; Goyal RK; Ahmed AA; Mitchell GS; St Peter SD; Flatt TG; Ahmed IA; Li W; Hendrickson RJ; August KJ; Myers GD
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33472856
[TBL] [Abstract][Full Text] [Related]
26. Clinical Pharmacology of Tisagenlecleucel in B-cell Acute Lymphoblastic Leukemia.
Mueller KT; Waldron E; Grupp SA; Levine JE; Laetsch TW; Pulsipher MA; Boyer MW; August KJ; Hamilton J; Awasthi R; Stein AM; Sickert D; Chakraborty A; Levine BL; June CH; Tomassian L; Shah SS; Leung M; Taran T; Wood PA; Maude SL
Clin Cancer Res; 2018 Dec; 24(24):6175-6184. PubMed ID: 30190371
[TBL] [Abstract][Full Text] [Related]
27. The journey to CAR T cell therapy: the pediatric and young adult experience with relapsed or refractory B-ALL.
Hucks G; Rheingold SR
Blood Cancer J; 2019 Jan; 9(2):10. PubMed ID: 30670684
[TBL] [Abstract][Full Text] [Related]
28. Integrating expert opinion with clinical trial data to extrapolate long-term survival: a case study of CAR-T therapy for children and young adults with relapsed or refractory acute lymphoblastic leukemia.
Cope S; Ayers D; Zhang J; Batt K; Jansen JP
BMC Med Res Methodol; 2019 Sep; 19(1):182. PubMed ID: 31477025
[TBL] [Abstract][Full Text] [Related]
29. Out-of-specification tisagenlecleucel does not compromise safety or efficacy in pediatric acute lymphoblastic leukemia.
Rossoff J; Baggott C; Prabhu S; Pacenta H; Phillips CL; Stefanski H; Talano JA; Moskop A; Margossian SP; Verneris MR; Myers GD; Karras N; Brown PA; Qayed M; Hermiston M; Satwani P; Krupski C; Keating AK; Wilcox R; Rabik CA; Fabrizio VA; Kunicki M; Chinnabhandar V; Goksenin AY; Curran KJ; Mackall CL; Laetsch TW; Schultz LM
Blood; 2021 Nov; 138(21):2138-2142. PubMed ID: 34499715
[No Abstract] [Full Text] [Related]
30. Tisagenlecleucel vs. historical standard of care in children and young adult patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.
V Stackelberg A; Jäschke K; Jousseaume E; Templin C; Jeratsch U; Kosmides D; Steffen I; Gökbuget N; Peters C
Leukemia; 2023 Dec; 37(12):2346-2355. PubMed ID: 37880478
[TBL] [Abstract][Full Text] [Related]
31. CAR-T Cell Therapies: An Overview of Clinical Studies Supporting Their Approved Use against Acute Lymphoblastic Leukemia and Large B-Cell Lymphomas.
Ahmad A; Uddin S; Steinhoff M
Int J Mol Sci; 2020 May; 21(11):. PubMed ID: 32486160
[TBL] [Abstract][Full Text] [Related]
32. The European Medicines Agency Review of Kymriah (Tisagenlecleucel) for the Treatment of Acute Lymphoblastic Leukemia and Diffuse Large B-Cell Lymphoma.
Ali S; Kjeken R; Niederlaender C; Markey G; Saunders TS; Opsata M; Moltu K; Bremnes B; Grønevik E; Muusse M; Håkonsen GD; Skibeli V; Kalland ME; Wang I; Buajordet I; Urbaniak A; Johnston J; Rantell K; Kerwash E; Schuessler-Lenz M; Salmonson T; Bergh J; Gisselbrecht C; Tzogani K; Papadouli I; Pignatti F
Oncologist; 2020 Feb; 25(2):e321-e327. PubMed ID: 32043764
[TBL] [Abstract][Full Text] [Related]
33. More Updates to Come of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia in the ELIANA Trial: Could the Statistical Methodology Be Further Improved?
Tong WH; Mertens BJ
J Clin Oncol; 2023 May; 41(13):2450-2451. PubMed ID: 36898080
[No Abstract] [Full Text] [Related]
34. Use of CD19-directed CAR T-Cell Therapy in an Infant With Refractory Acute Lymphoblastic Leukemia.
Breese EH; Krupski C; Nelson AS; Perentesis JP; Phillips CL
J Pediatr Hematol Oncol; 2021 May; 43(4):152-154. PubMed ID: 32496443
[TBL] [Abstract][Full Text] [Related]
35. [Eligibility of patients for CAR T-cell: Expert opinion-based collaborative work by the SFGM-TC].
Beauvais D; Bachy E; Baruchel A; Bay JO; Caillot D; Cartron G; Damaj G; Furst S; Le Gouill S; Morschhauser F; Rabian F; Rubio MT; Thieblemont C; Yakoub-Agha I
Bull Cancer; 2021; 108(7-8):725-729. PubMed ID: 33423776
[TBL] [Abstract][Full Text] [Related]
36. [Medium-term follow-up of patients treated with chimeric antigen receptor T cells (CAR T cells): Recommendations of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)].
Alsuliman T; Drieu La Rochelle L; Campidelli A; Duléry R; Fayard A; Mamez AC; Mear JB; Schneider PO; Trevet A; Vicente C; Yakoub-Agha I
Bull Cancer; 2021 Dec; 108(12S):S65-S71. PubMed ID: 33678408
[TBL] [Abstract][Full Text] [Related]
37. Patient-reported quality of life after tisagenlecleucel infusion in children and young adults with relapsed or refractory B-cell acute lymphoblastic leukaemia: a global, single-arm, phase 2 trial.
Laetsch TW; Myers GD; Baruchel A; Dietz AC; Pulsipher MA; Bittencourt H; Buechner J; De Moerloose B; Davis KL; Nemecek E; Driscoll T; Mechinaud F; Boissel N; Rives S; Bader P; Peters C; Sabnis HS; Grupp SA; Yanik GA; Hiramatsu H; Stefanski HE; Rasouliyan L; Yi L; Shah S; Zhang J; Harris AC
Lancet Oncol; 2019 Dec; 20(12):1710-1718. PubMed ID: 31606419
[TBL] [Abstract][Full Text] [Related]
38. Estimation of total costs in patients with relapsed or refractory diffuse large B-cell lymphoma receiving tisagenlecleucel from a US hospital's perspective.
Yang H; Hao Y; Chai X; Qi CZ; Wu EQ
J Med Econ; 2020 Sep; 23(9):1016-1024. PubMed ID: 32397772
[No Abstract] [Full Text] [Related]
39. Higher doses of tisagenlecleucel are associated with improved outcomes: a report from the pediatric real-world CAR consortium.
Stefanski HE; Eaton A; Baggott C; Rossoff J; Verneris MR; Prabhu S; Pacenta HL; Phillips CL; Talano JA; Moskop A; Margossian SP; Myers GD; Karras NA; Brown PA; Qayed M; Hermiston M; Satwani P; Krupski MC; Keating AK; Wilcox R; Rabik CA; Fabrizio VA; Chinnabhandar V; Goksenin AY; Curran KJ; Mackall CL; Laetsch TW; Schultz LM
Blood Adv; 2023 Feb; 7(4):541-548. PubMed ID: 35938863
[TBL] [Abstract][Full Text] [Related]
40. Three-Year Update of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia in the ELIANA Trial.
Laetsch TW; Maude SL; Rives S; Hiramatsu H; Bittencourt H; Bader P; Baruchel A; Boyer M; De Moerloose B; Qayed M; Buechner J; Pulsipher MA; Myers GD; Stefanski HE; Martin PL; Nemecek E; Peters C; Yanik G; Khaw SL; Davis KL; Krueger J; Balduzzi A; Boissel N; Tiwari R; O'Donovan D; Grupp SA
J Clin Oncol; 2023 Mar; 41(9):1664-1669. PubMed ID: 36399695
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
